{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:17:38Z","timestamp":1783081058131,"version":"3.54.6"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006096","name":"Shiraz University of Medical Sciences Shiraz Transplant Research Center","doi-asserted-by":"publisher","award":["21994"],"award-info":[{"award-number":["21994"]}],"id":[{"id":"10.13039\/501100006096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.SUMS.MED.REC.1399.622"],"award-info":[{"award-number":["IR.SUMS.MED.REC.1399.622"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.virusres.2026.199739","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:26:53Z","timestamp":1777494413000},"page":"199739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study"],"prefix":"10.1016","volume":"368","author":[{"given":"Ali","family":"Jangjou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payman","family":"Izadpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Moqhadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosein","family":"Faramarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Fahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ghazipoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadid","family":"Hamrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-2297","authenticated-orcid":false,"given":"Hesam","family":"Kamyab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.virusres.2026.199739_bib0001","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4093\/dmj.2013.37.3.190","article-title":"Corrected QT interval prolongation during severe hypoglycemia without hypokalemia in patients with type 2 diabetes","volume":"37","author":"Beom","year":"2013","journal-title":"Diabetes Metab. J."},{"issue":"19","key":"10.1016\/j.virusres.2026.199739_bib0002","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.virusres.2026.199739_bib0003","first-page":"1023","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review","volume":"4","author":"Chandwani","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"issue":"3","key":"10.1016\/j.virusres.2026.199739_bib0004","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2276624","article-title":"Evolution of global scientific collaboration in mRNA vaccine research: insights from bibliometric and social network analysis (2010\u223c2023)","volume":"19","author":"Chen","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"9","key":"10.1016\/j.virusres.2026.199739_bib0005","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.hrthm.2020.05.014","article-title":"QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine\/azithromycin","volume":"17","author":"Chorin","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.virusres.2026.199739_bib0006","article-title":"Making sound public health policy decisions for COVID-19 vaccination: vaccine effectiveness, safety, affordability, programmatic logistics and roll-out globally","author":"Choudhary","year":"2021","journal-title":"J. Travel Med."},{"key":"10.1016\/j.virusres.2026.199739_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2024.102694","article-title":"Zoonotic diseases in a changing climate scenario: revisiting the interplay between environmental variables and infectious disease dynamics","volume":"58","author":"Choudhary","year":"2024","journal-title":"Travel Med. Infect. Dis."},{"issue":"8","key":"10.1016\/j.virusres.2026.199739_bib0008","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"63","author":"Cvetkovic","year":"2003","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.virusres.2026.199739_bib0009","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.therap.2020.05.002","article-title":"\"Off-label\" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French network of pharmacovigilance centers","volume":"75","author":"G\u00e9rard","year":"2020","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.virusres.2026.199739_bib0010","article-title":"Cardiovascular adverse effects of lopinavir\/ritonavir and hydroxychloroquine in COVID-19 patients: cases from a single pharmacovigilance centre","volume":"2021","author":"Istampoulouoglou","year":"2021","journal-title":"Glob. Cardiol. Sci. Pr."},{"issue":"4","key":"10.1016\/j.virusres.2026.199739_bib0011","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/acs.chemrestox.1c00028","article-title":"Inhibition of CYP3A7 DHEA-S oxidation by lopinavir and ritonavir: an alternative mechanism for adrenal impairment in HIV antiretroviral-treated neonates","volume":"34","author":"Kandel","year":"2021","journal-title":"Chem. Res. Toxicol."},{"issue":"4","key":"10.1016\/j.virusres.2026.199739_bib0012","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3904\/kjim.2020.157","article-title":"In vitro activity of lopinavir\/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses","volume":"35","author":"Kang","year":"2020","journal-title":"Korean J. Intern. Med."},{"issue":"6","key":"10.1016\/j.virusres.2026.199739_bib0013","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"49","author":"Martin-Loeches","year":"2023","journal-title":"Intensive Care Med."},{"issue":"9","key":"10.1016\/j.virusres.2026.199739_bib0014","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.virusres.2026.199739_bib0015","series-title":"Viral Drug Delivery Systems: Advances in Treatment of Infectious Diseases","first-page":"339","article-title":"The use of azithromycin and lopinavir-ritonavir in the treatment of COVID-19","author":"Miatmoko","year":"2023"},{"issue":"6","key":"10.1016\/j.virusres.2026.199739_bib0016","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jiph.2021.03.015","article-title":"Efficacy and safety of lopinavir-ritonavir in COVID-19: a systematic review of randomized controlled trials","volume":"14","author":"Patel","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.virusres.2026.199739_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115597","article-title":"Nanovaccines: a game changing approach in the fight against infectious diseases","volume":"167","author":"Priyanka","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.virusres.2026.199739_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2023.102550","article-title":"mRNA vaccines as an armor to combat the infectious diseases","volume":"52","author":"Priyanka","year":"2023","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.virusres.2026.199739_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2021.101983","article-title":"Evolution of SARS-CoV-2: a prediction on the lineages and vaccine effectiveness","volume":"40","author":"Priyanka","year":"2021","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.virusres.2026.199739_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101911","article-title":"Protective immunity against COVID-19: unravelling the evidences for humoral vs. cellular components","volume":"39","author":"Priyanka","year":"2021","journal-title":"Travel Med. Infect. Dis."},{"issue":"31","key":"10.1016\/j.virusres.2026.199739_bib0021","article-title":"Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: a systematic review","volume":"100","author":"Ridjab","year":"2021","journal-title":"Med. (Baltim.)"},{"issue":"1","key":"10.1016\/j.virusres.2026.199739_bib0022","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.clpt.6100263","article-title":"Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies","volume":"83","author":"Sarapa","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.virusres.2026.199739_bib0023","article-title":"The ECG characteristics of patients with isolated hypomagnesemia","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.virusres.2026.199739_bib0024","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers","volume":"42","author":"Yeh","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170226000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170226000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:25:23Z","timestamp":1783077923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170226000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"alternative-id":["S0168170226000584"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2026.199739","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2026.199739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"199739"}}